Minocin is a semisynthetic antibiotic of tetracycline group. Was first introduced in 1967, is currently used to treat certain bacterial infections, and rickettsial and amebiasis. As doxycycline belongs to the tetracycline of prolonged effect.
In comparison with other drugs of the group of the tetracyclines, minocycline has a slightly broader spectrum of antibacterial activity, including activity against meningococcal disease, but its use requires caution because of specific side effects and to prevent the emergence of resistance of microorganisms to him.
Is a derivative of tetracycline, differs structurally from it in the presence of another dimethylaminopropyl 7 position (and the lack of 6-methyl – and 6-gidroksipropil). In finished dosage forms used as hydrochloride dihydrate.
Molecule of minocycline compared to other tetracyclines, has the most pronounced lipophilic properties, resulting in differences in pharmacokinetics from other medications of this group.
Side effects Minocin.
Often have a variety of vestibular symptoms: dizziness, vertigo (more than 30 % of cases), and tooth discoloration in children (over 10 %).
In Norway, the preparations, the content of minocycline in 1989 were prohibited from being registered because the relevant adverse effects were typically more severe than those of the other tetracyclines. However, the who notes that this product has been successfully registered in many countries, cases of refusal of registration not recorded elsewhere, and describes the symptoms associated with taking minocycline, as a rule, not characterized as severe.
In the Philippines, minocycline, like other tetracyclines, since 1978 is banned for use in Pediatrics, because all these drugs tend to accumulate in a developing bone tissue of children (as well as the fetus in pregnant women) that may result in a delay in bone growth and staining of dental tissues.